The present invention discloses the use of plasminogen to regulate GLP-1/GLP-1R and treat a GLP-1/GLP-1R-related condition.

Methods for diagnosing and treating Alzheimer's disease are provided. In particular, methods of restoring blood-brain barrier integrity and/or promoting vascular reversion in a person suffering from Alzheimer's disease by administering an anti-angiogenic agent or an agent that is capable of restoring tight junction integrity. Methods of preventing or delaying the onset of Alzheimer's disease in a subject are also provided.

The present disclosure provides pharmaceutical compositions of niclosamide and a protein that may be administered via inhalation These compositions may be used in nebulized, nasal, and inhaler formats. These compositions may be used to treat one or more diseases or disorders such as a viral infection or cancer.

The present disclosure provides pharmaceutical compositions of niclosamide and a protein that may be administered via inhalation These compositions may be used in nebulized, nasal, and inhaler formats. These compositions may be used to treat one or more diseases or disorders such as a viral infection or cancer.

The present invention relates to a method for preventing and treating tissue and organ fibrosis, comprising administering an effective amount of plasminogen to a subject.

The present invention provides uses of plasminogen in preventing and/or treating osteoporosis and diseases related to the osteoporosis. The present invention also provides a drug and a product for preventing and/or treating osteoporosis.

The present invention relates to a method for preventing atherosclerosis, comprising administeringh a prophylactically effective amount of plasminogen to a subject susceptible to atherosclerosis. The present invention further relates to a medicament, a pharmaceutical composition, an article of manufacture and a kit comprising plasminogen which are useful for preventing atherosclerosis.

The present invention relates a method for preventing and/or treating a renal tissue injury in a subject, comprising administering an effective amount of plasminogen to the subject, wherein the subject has a risk of the renal tissue injury, is suspected of having the renal tissue injury or suffers from the renal tissue injury. The present invention further relates to a medicament, a pharmaceutical composition, an article of manufacture, and a kit comprising plasminogen which are useful for preventing and/or treating a renal tissue injury and its related conditions in a subject.

The present invention relates to a method for preventing and/or treating hyperlipemia and its related conditions in a subject, comprising administering a prophylactically and/or therapeutically effective amount of plasminogen to the subject susceptible to hyperlipemia, suffers from hyperlipemia or other diseases accompanied by hyperlipemia. The present invention further relates to a medicament, a pharmaceutical composition, an article of manufacture, and a kit comprising plasminogen which are useful for preventing and/or treating hyperlipemia and its related conditions in a subject.

A pharmaceutical composition for treating an ischemic tissue, comprising: a core component and a matrix component, wherein the core component includes a heparin or derivative thereof and the matrix component includes a hyaluronan or derivative thereof, the pharmaceutical composition having a viscosity greater than 10 mPa-s.